Loading...
•
Dec 31, 2021
Protagonist Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
Key Takeaways
Protagonist Therapeutics reported its fourth quarter financial results and provided a corporate update, highlighting the advancement of rusfertide into a Phase 3 registrational study, completion of enrollment for PN-943 Phase 2 study, and progression of PN-235 into a Phase 2b study by Janssen.
Rusfertide is moving into a Phase 3 registrational study for polycythemia vera.
Enrollment is complete for PN-943 Phase 2 proof-of-concept study in ulcerative colitis.
Janssen is progressing PN-235 into a Phase 2b study in plaque psoriasis.
The company anticipates topline data readout from the Phase 2 IDEAL study of PN-943 in ulcerative colitis in the second quarter of this year.
Forward Guidance
Protagonist Therapeutics plans to continue to demonstrate strength of execution across all current and emerging assets in its pipeline, thereby maximizing the opportunities ahead for substantial value creation this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...